Ocugen, Inc. (OCGN) is the 218th largest of 300 Gene and Cell Therapy companies by market capitalisation, at 458.91 Mn, behind Atea Pharmaceuticals, Inc. at 467.50 Mn. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 10.61 Bn | 0.00 Mn | 24.07 | 9.76 Bn |
| 2 | CRSP | CRISPR Therapeutics AG | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 5.39 Bn | 0.00 Mn | 402.57 | 5.39 Bn |
| 3 | LEGN | Legend Biotech Corp | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.97 Bn | 0.00 Mn | 3.12 | 3.00 Bn |
| 4 | IOVA | Iovance Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.95 Bn | 0.00 Mn | 12.17 | 3.66 Bn |
| 5 | BEAM | Beam Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.10 Bn | 0.00 Mn | 19.86 | 3.10 Bn |
| 6 | QURE | uniQure N.V. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.95 Bn | 0.00 Mn | 157.84 | 2.95 Bn |
| 7 | PGEN | Precigen, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | 0.00 Mn | 29.54 | 2.53 Bn |
| 8 | SRPT | Sarepta Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.36 Bn | 0.00 Mn | 1.20 | 1.57 Bn |
| 9 | MESO | Mesoblast Ltd | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.24 Bn | 0.00 Mn | 18.46 | 2.14 Bn |
| 10 | TSHA | Taysha Gene Therapies, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.06 Bn | 0.00 Mn | 376.45 | 2.06 Bn |
| 11 | VCEL | Vericel Corp | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.05 Bn | 0.00 Mn | 6.69 | 1.89 Bn |
| 12 | NTLA | Intellia Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | 0.00 Mn | 28.53 | 1.70 Bn |
| 13 | SLDB | Solid Biosciences Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.48 Bn | 0.00 Mn | — | 1.48 Bn |
| 14 | MGTX | MeiraGTx Holdings plc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.27 Bn | 0.00 Mn | 3.17 | 1.13 Bn |
| 15 | IMTX | Immatics N.V. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | 0.00 Mn | 24.04 | 0.71 Bn |
| 16 | SANA | Sana Biotechnology, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.14 Bn | 0.00 Mn | — | 1.14 Bn |
| 17 | FDMT | 4D Molecular Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.05 Bn | 0.00 Mn | 11.45 | 0.69 Bn |
| 18 | CADL | Candel Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | 0.00 Mn | — | 0.95 Bn |
| 19 | IMMX | Immix Biopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | 0.00 Mn | — | 0.89 Bn |
| 20 | NGNE | Neurogene Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.86 Bn | 0.00 Mn | — | 0.86 Bn |
| 21 | PRME | Prime Medicine, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | 0.00 Mn | 160.56 | 0.65 Bn |
| 22 | ALLO | Allogene Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.65 Bn | 0.00 Mn | 139.65 | 0.65 Bn |
| 23 | AUTL | Autolus Therapeutics plc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | 0.00 Mn | 5.31 | 0.39 Bn |
| 24 | BNTC | Benitec Biopharma Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | 0.00 Mn | — | 0.59 Bn |
| 25 | CAPR | Capricor Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | — | 0.54 Bn |
| 26 | CABA | Cabaletta Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | 0.00 Mn | — | 0.52 Bn |
| 27 | KYTX | Kyverna Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | 0.00 Mn | — | 0.51 Bn |
| 28 | RGNX | REGENXBIO Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | 2.50 | 0.37 Bn |
| 29 | OCGN | Ocugen, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 0.00 Mn | 100.20 | 0.36 Bn |
| 30 | IRD | Opus Genetics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 45.34 | 0.36 Bn |
| 31 | ARTV | Artiva Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | — | 0.44 Bn |
| 32 | IPSC | Century Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | — | 0.18 Bn |
| 33 | RCKT | Rocket Pharmaceuticals, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | 0.00 Mn | — | 0.44 Bn |
| 34 | LXEO | Lexeo Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | 0.00 Mn | — | 0.42 Bn |
| 35 | PROK | Prokidney Corp. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | 464.12 | 0.38 Bn |
| 36 | ABEO | Abeona Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 13.41 | 0.20 Bn |
| 37 | LYEL | Lyell Immunopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 12,443.49 | 0.34 Bn |
| 38 | CLLS | Cellectis S.A. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | 0.00 Mn | 5.47 | 0.16 Bn |
| 39 | FATE | Fate Therapeutics Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 46.19 | 0.30 Bn |
| 40 | EDIT | Editas Medicine, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | — | — | 0.14 Bn |
| 41 | NWBO | Northwest Biotherapeutics Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 0.00 Mn | 128.04 | 0.28 Bn |
| 42 | RNAC | Cartesian Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | 184.14 | 0.27 Bn |
| 43 | LCTX | Lineage Cell Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 0.00 Mn | 20.69 | 0.21 Bn |
| 44 | TARA | Protara Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | 0.00 Mn | — | 0.24 Bn |
| 45 | NKTX | Nkarta, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | 0.00 Mn | — | 0.22 Bn |
| 46 | VYGR | Voyager Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 0.00 Mn | 6.11 | 0.09 Bn |
| 47 | DTIL | Precision Biosciences Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 0.00 Mn | 4.29 | 0.11 Bn |
| 48 | CRBU | Caribou Biosciences, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | 0.00 Mn | 15.70 | 0.05 Bn |
| 49 | TNYA | Tenaya Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 111.46 | 0.15 Bn |
| 50 | ZSQR | Z Squared Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 52.66 | 0.13 Bn |
| 51 | ATRA | Atara Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | 0.00 Mn | 23.71 | 0.13 Bn |
| 52 | HUMA | Humacyte, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 Mn | 66.64 | 0.14 Bn |
| 53 | ENGN | enGene Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | 0.00 Mn | — | 0.13 Bn |
| 54 | ACET | Adicet Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | -0.02 Bn |
| 55 | ANIX | Anixa Biosciences Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | 0.00 Mn | — | 0.10 Bn |
| 56 | INMB | Inmune Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | — | 0.05 Bn |
| 57 | INKT | MiNK Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | — | 0.06 Bn |
| 58 | APTN | Adaptin Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 0.00 Mn | — | 0.06 Bn |
| 59 | TCRX | TScan Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | 0.00 Mn | 7.27 | 0.05 Bn |
| 60 | SGMOQ | Sangamo Therapeutics, Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 1.13 | 0.02 Bn |
| 61 | CELU | Celularity Inc | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 1.66 | 0.04 Bn |
| 62 | MGX | Metagenomi Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 0.00 Mn | 2.02 | 0.04 Bn |
| 63 | ESLA | Estrella Immunopharma, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 64 | TVGN | Tevogen Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.00 Mn | — | 0.03 Bn |
| 65 | INAB | In8Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 66 | MRKR | Marker Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.01 Bn |
| 67 | LGVN | Longeveron Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | 18.17 | 0.01 Bn |
| 68 | GNTA | Genenta Science S.p.A. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | -0.01 Bn |
| 69 | PASG | Passage BIO, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | 0.00 Mn | — | 0.02 Bn |
| 70 | ADIA | Adia Nutrition, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 69.62 | 0.01 Bn |
| 71 | PLUR | Pluri Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 9.06 | 0.00 Bn |
| 72 | FBLG | FibroBiologics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | — | 0.01 Bn |
| 73 | SNTI | Senti Biosciences Holdings, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 622.71 | 0.01 Bn |
| 74 | GDTC | CytoMed Therapeutics Ltd | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 41.92 | 0.01 Bn |
| 75 | ZEOX | Zeo ScientifiX, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 1.34 | 0.01 Bn |
| 76 | LNAI | Lunai Bioworks Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.00 Mn | 86.37 | 0.00 Bn |
| 77 | TPST | Tempest Therapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | — | 0.00 Bn |
| 78 | PMCB | PharmaCyte Biotech, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | — | 0.00 Bn |
| 79 | MBIO | Mustang Bio, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | — | 0.00 Bn |
| 80 | ISCO | International Stem Cell CORP | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | 0.32 | 0.00 Bn |
| 81 | CLDI | Calidi Biotherapeutics, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | — | 0.00 Bn |
| 82 | GNPX | Genprex, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -0.01 Bn |
| 83 | CELZ | Creative Medical Technology Holdings, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | 517.47 | 0.00 Bn |
| 84 | RMTG | Regenerative Medical Technology Group Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | 0.12 | 0.00 Bn |
| 85 | ERNAW | Ernexa Therapeutics Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | — | 0.00 Bn |
| 86 | BRTX | BioRestorative Therapies, Inc. | primary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 Mn | 0.18 | 0.00 Bn |
| 87 | JNJ | Johnson & Johnson | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 663.34 Bn | 0.00 Mn | 6.77 | 642.58 Bn |
| 88 | ABBV | AbbVie Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 453.74 Bn | 0.00 Mn | 7.05 | 447.17 Bn |
| 89 | MRK | Merck & Co., Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 371.80 Bn | 0.00 Mn | 5.59 | 364.66 Bn |
| 90 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 236.46 Bn | 0.00 Mn | 6.21 | 222.47 Bn |
| 91 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.36 Bn | 0.00 Mn | 6.15 | 184.18 Bn |
| 92 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 138.47 Bn | 0.00 Mn | 11.00 | 130.62 Bn |
| 93 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 85.18 Bn | 0.00 Mn | 5.48 | 77.19 Bn |
| 94 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.38 Bn | 0.00 Mn | 12.13 | 58.19 Bn |
| 95 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 58.09 Bn | 0.00 Mn | 26.07 | 52.95 Bn |
| 96 | SNY | Sanofi | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 54.00 Bn | 0.00 Mn | 1.01 | 46.62 Bn |
| 97 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 42.41 Bn | 0.00 Mn | 2.45 | 38.75 Bn |
| 98 | ONC | BeOne Medicines Ltd. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 40.02 Bn | 0.00 Mn | 6.53 | 34.92 Bn |
| 99 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.57 Bn | 0.00 Mn | 7.40 | 32.27 Bn |
| 100 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.63 Bn | 0.00 Mn | 3.25 | 31.34 Bn |
| 101 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.48 Bn | 0.00 Mn | 24.15 | 26.32 Bn |
| 102 | INCY | Incyte Corp | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 25.44 Bn | 0.00 Mn | 4.37 | 20.91 Bn |
| 103 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.18 Bn | 0.00 Mn | 2,305.26 | 25.18 Bn |
| 104 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.06 Bn | 0.00 Mn | 8.10 | 11.41 Bn |
| 105 | UTHR | UNITED THERAPEUTICS Corp | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 20.83 Bn | 0.00 Mn | 6.60 | 18.16 Bn |
| 106 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 18.81 Bn | 0.00 Mn | 2.21 | 18.40 Bn |
| 107 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.39 Bn | 0.00 Mn | 13.42 | 15.45 Bn |
| 108 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.79 Bn | 0.00 Mn | 12.30 | 14.96 Bn |
| 109 | NBIX | Neurocrine Biosciences Inc | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.76 Bn | 0.00 Mn | 4.67 | 15.37 Bn |
| 110 | JAZZ | Jazz Pharmaceuticals plc | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.60 Bn | 0.00 Mn | 3.39 | 13.98 Bn |
| 111 | EXEL | Exelixis, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 14.81 Bn | 0.00 Mn | 6.08 | 13.97 Bn |
| 112 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.65 Bn | 0.00 Mn | 20.55 | 13.93 Bn |
| 113 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.67 Bn | — | — | 12.98 Bn |
| 114 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.92 Bn | 0.00 Mn | 7.77 | 12.69 Bn |
| 115 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.88 Bn | 0.00 Mn | 3.78 | 12.01 Bn |
| 116 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.40 Bn | 0.00 Mn | 18.52 | 10.80 Bn |
| 117 | AXSM | Axsome Therapeutics, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.75 Bn | 0.00 Mn | 13.84 | 10.43 Bn |
| 118 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.59 Bn | 0.00 Mn | 3.37 | 9.99 Bn |
| 119 | GPCR | Structure Therapeutics Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.32 Bn | 0.00 Mn | — | 10.32 Bn |
| 120 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.28 Bn | 0.00 Mn | — | 9.52 Bn |
| 121 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | 0.00 Mn | — | 9.20 Bn |
| 122 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.95 Bn | 0.00 Mn | 2.72 | 9.78 Bn |
| 123 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.61 Bn | 0.00 Mn | 34.07 | 9.61 Bn |
| 124 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.60 Bn | 0.00 Mn | 10.98 | 7.55 Bn |
| 125 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.83 Bn | 0.00 Mn | — | 8.83 Bn |
| 126 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.51 Bn | 0.00 Mn | 51.33 | 8.15 Bn |
| 127 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.07 Bn | 0.00 Mn | — | 8.07 Bn |
| 128 | ABVX | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.99 Bn | 0.00 Mn | — | 7.99 Bn |
| 129 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.97 Bn | 0.00 Mn | 9.97 | 7.29 Bn |
| 130 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.53 Bn | 0.00 Mn | — | 7.53 Bn |
| 131 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.24 Bn | 0.00 Mn | — | 7.24 Bn |
| 132 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.02 Bn | 0.00 Mn | 29.27 | 6.69 Bn |
| 133 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.64 Bn | 0.00 Mn | 4,772.92 | 6.64 Bn |
| 134 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.60 Bn | 0.00 Mn | 1,060.37 | 6.60 Bn |
| 135 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.40 Bn | 0.00 Mn | 10.35 | 5.96 Bn |
| 136 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.05 Bn | 0.00 Mn | 7.20 | 5.53 Bn |
| 137 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.96 Bn | 0.00 Mn | — | 5.96 Bn |
| 138 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.94 Bn | 0.00 Mn | — | 5.94 Bn |
| 139 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.88 Bn | 0.00 Mn | 1,170.87 | 5.70 Bn |
| 140 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.85 Bn | — | — | 4.12 Bn |
| 141 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.78 Bn | 0.00 Mn | 5.73 | 3.55 Bn |
| 142 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.76 Bn | 0.00 Mn | 19.84 | 4.41 Bn |
| 143 | GRFS | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.31 Bn | 0.00 Mn | 0.32 | 4.15 Bn |
| 144 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.25 Bn | 0.00 Mn | — | 5.25 Bn |
| 145 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.04 Bn | 0.00 Mn | — | 5.04 Bn |
| 146 | RADX | Radiopharm Theranostics Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.33 Bn | 0.00 Mn | 20,980.03 | 4.33 Bn |
| 147 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.18 Bn | 0.00 Mn | 1,161.10 | 4.18 Bn |
| 148 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.09 Bn | — | — | 3.69 Bn |
| 149 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.06 Bn | 0.00 Mn | — | 4.06 Bn |
| 150 | TLX | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | — | — | 3.74 Bn |
| 151 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.02 Bn | 0.00 Mn | — | 4.02 Bn |
| 152 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.87 Bn | 0.00 Mn | 373.95 | 3.87 Bn |
| 153 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.79 Bn | 0.00 Mn | — | 3.79 Bn |
| 154 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.74 Bn | 0.00 Mn | 31.96 | 3.04 Bn |
| 155 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.68 Bn | 0.00 Mn | 15.73 | 2.85 Bn |
| 156 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.49 Bn | 0.00 Mn | 52.71 | 3.49 Bn |
| 157 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.37 Bn | 0.00 Mn | 62.56 | 2.35 Bn |
| 158 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.12 Bn | 0.00 Mn | 6.73 | 2.88 Bn |
| 159 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.10 Bn | 0.00 Mn | 19,590.55 | 3.10 Bn |
| 160 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.06 Bn | 0.00 Mn | — | 3.06 Bn |
| 161 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.03 Bn | 0.00 Mn | 593.06 | 2.51 Bn |
| 162 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.97 Bn | 0.00 Mn | — | 2.97 Bn |
| 163 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | 0.00 Mn | 6.53 | 2.23 Bn |
| 164 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.90 Bn | 0.00 Mn | 78.89 | 2.46 Bn |
| 165 | TAK | Takeda Pharmaceutical Co Ltd | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | 0.00 Mn | 0.06 | -3.16 Bn |
| 166 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.62 Bn | 0.00 Mn | — | 2.62 Bn |
| 167 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.58 Bn | 0.00 Mn | — | 2.58 Bn |
| 168 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.57 Bn | 0.00 Mn | 10.22 | 2.46 Bn |
| 169 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | 0.00 Mn | 4.75 | 2.19 Bn |
| 170 | SUPN | Supernus Pharmaceuticals, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | 0.00 Mn | 3.22 | 2.17 Bn |
| 171 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.45 Bn | 0.00 Mn | 44.90 | 1.77 Bn |
| 172 | HRMY | Harmony Biosciences Holdings, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.45 Bn | 0.00 Mn | 2.55 | 1.64 Bn |
| 173 | HCM | HUTCHMED (China) Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | 0.00 Mn | 3.41 | 2.43 Bn |
| 174 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | 0.00 Mn | 33.96 | 2.42 Bn |
| 175 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.40 Bn | 0.00 Mn | 46.07 | 2.40 Bn |
| 176 | NUVB | Nuvation Bio Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.38 Bn | 0.00 Mn | 14.01 | 2.38 Bn |
| 177 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.37 Bn | 0.00 Mn | — | 2.10 Bn |
| 178 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.27 Bn | 0.00 Mn | — | 2.27 Bn |
| 179 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | 0.00 Mn | 11.79 | 2.12 Bn |
| 180 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.21 Bn | 0.00 Mn | — | 2.21 Bn |
| 181 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | 0.00 Mn | 4.28 | 2.06 Bn |
| 182 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 0.00 Mn | 0.34 | 0.67 Bn |
| 183 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 0.00 Mn | 108.62 | 2.17 Bn |
| 184 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.13 Bn | 0.00 Mn | 57.49 | 1.86 Bn |
| 185 | AUPH | Aurinia Pharmaceuticals Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | 0.00 Mn | 6.74 | 1.66 Bn |
| 186 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | 0.00 Mn | — | 1.73 Bn |
| 187 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | 0.00 Mn | 2,085.86 | 2.09 Bn |
| 188 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.02 Bn | 0.00 Mn | 19.28 | 1.65 Bn |
| 189 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | 0.00 Mn | 20.05 | 1.97 Bn |
| 190 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.96 Bn | 0.00 Mn | 71.02 | 1.67 Bn |
| 191 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.94 Bn | 0.00 Mn | — | 1.94 Bn |
| 192 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.93 Bn | 0.00 Mn | 35.26 | 1.38 Bn |
| 193 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | 0.00 Mn | 6.32 | 1.92 Bn |
| 194 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.91 Bn | 0.00 Mn | 1,465.41 | 1.91 Bn |
| 195 | LKFT | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.00 Mn | 1.63 | 1.88 Bn |
| 196 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.85 Bn | 0.00 Mn | 4.28 | 0.97 Bn |
| 197 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.83 Bn | 0.00 Mn | — | 1.29 Bn |
| 198 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.83 Bn | 0.00 Mn | 7.25 | 1.28 Bn |
| 199 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.79 Bn | 0.00 Mn | — | 1.79 Bn |
| 200 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | 0.00 Mn | 1,025.82 | 1.76 Bn |
| 201 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.72 Bn | 0.00 Mn | — | 1.36 Bn |
| 202 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | 0.00 Mn | 4.06 | 0.96 Bn |
| 203 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | 0.00 Mn | 16.77 | 1.66 Bn |
| 204 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | 0.00 Mn | 8.14 | 1.34 Bn |
| 205 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | 0.00 Mn | 530.56 | 1.61 Bn |
| 206 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | 0.00 Mn | — | 1.23 Bn |
| 207 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | 0.00 Mn | — | 1.57 Bn |
| 208 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | 0.00 Mn | 20.12 | 1.29 Bn |
| 209 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.56 Bn | 0.00 Mn | 2.18 | 1.27 Bn |
| 210 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | 0.00 Mn | 77.46 | 1.55 Bn |
| 211 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.52 Bn | 0.00 Mn | — | 1.52 Bn |
| 212 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.50 Bn | 0.00 Mn | 5.79 | 1.09 Bn |
| 213 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.48 Bn | 0.00 Mn | — | 1.48 Bn |
| 214 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | 0.00 Mn | — | 1.46 Bn |
| 215 | ALMS | Alumis Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.42 Bn | 0.00 Mn | 170.77 | 0.92 Bn |
| 216 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.40 Bn | 0.00 Mn | 48.89 | 0.77 Bn |
| 217 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | 0.00 Mn | 889.25 | 1.19 Bn |
| 218 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 0.00 Mn | — | 1.38 Bn |
| 219 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 0.00 Mn | 35.80 | 1.38 Bn |
| 220 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | 0.00 Mn | — | 1.37 Bn |
| 221 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | 0.00 Mn | — | 1.36 Bn |
| 222 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | 0.00 Mn | — | 1.36 Bn |
| 223 | CRVS | Corvus Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | 0.00 Mn | — | 1.12 Bn |
| 224 | JANX | Janux Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.27 Bn | 0.00 Mn | 52.84 | 1.27 Bn |
| 225 | MNKD | Mannkind Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | 0.00 Mn | 3.21 | 1.15 Bn |
| 226 | JBIO | Jade Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | 0.00 Mn | — | 1.21 Bn |
| 227 | CLYM | Climb Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | 0.00 Mn | — | 1.18 Bn |
| 228 | MLTX | MoonLake Immunotherapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.11 Bn | 0.00 Mn | — | 0.57 Bn |
| 229 | OKYO | OKYO Pharma Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.05 Bn | 0.00 Mn | — | 1.05 Bn |
| 230 | GERN | Geron Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.05 Bn | 0.00 Mn | 4.32 | 0.75 Bn |
| 231 | PCRX | Pacira BioSciences, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.04 Bn | 0.00 Mn | 1.40 | 0.79 Bn |
| 232 | ABUS | Arbutus Biopharma Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | 0.00 Mn | 5.61 | 0.93 Bn |
| 233 | MNPR | Monopar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 0.00 Mn | — | 0.95 Bn |
| 234 | WVE | Wave Life Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.99 Bn | 0.00 Mn | 15.21 | 0.63 Bn |
| 235 | ANNX | Annexon, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | 0.00 Mn | — | 0.98 Bn |
| 236 | ARDX | Ardelyx, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.93 Bn | 0.00 Mn | 2.07 | 0.65 Bn |
| 237 | RIGL | Rigel Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.90 Bn | 0.00 Mn | 3.26 | 0.81 Bn |
| 238 | STTK | Shattuck Labs, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | 0.00 Mn | 885.09 | 0.89 Bn |
| 239 | TBPH | Theravance Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 8.46 | 0.50 Bn |
| 240 | ACRS | Aclaris Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 0.00 Mn | 107.41 | 0.88 Bn |
| 241 | AVTX | Avalo Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.84 Bn | 0.00 Mn | — | 0.84 Bn |
| 242 | VSTM | Verastem, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | 0.00 Mn | 9.31 | 0.68 Bn |
| 243 | CTMX | CytomX Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | 0.00 Mn | 44.44 | 0.48 Bn |
| 244 | PHAR | Pharming Group N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | 0.00 Mn | 2.39 | 0.64 Bn |
| 245 | ZURA | Zura Bio Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | 0.00 Mn | — | 0.79 Bn |
| 246 | ZVRA | Zevra Therapeutics, Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.73 Bn | 0.00 Mn | 5.39 | 0.51 Bn |
| 247 | BBOT | BridgeBio Oncology Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | 0.00 Mn | — | 0.50 Bn |
| 248 | AURA | Aura Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | 0.00 Mn | — | 0.65 Bn |
| 249 | IRWD | Ironwood Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.70 Bn | 0.00 Mn | 1.80 | 0.62 Bn |
| 250 | SLN | Silence Therapeutics plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 1,122.93 | 0.62 Bn |
| 251 | ASMB | Assembly Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | 0.00 Mn | 9.21 | 0.37 Bn |
| 252 | CRMD | CorMedix Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | 0.00 Mn | 1.77 | 0.41 Bn |
| 253 | ALT | Altimmune, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | 0.00 Mn | — | 0.64 Bn |
| 254 | CBIO | Crescent Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | 0.00 Mn | 612.11 | 0.46 Bn |
| 255 | OCS | Oculis Holding AG | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | -0.36 Mn | — | 0.35 Bn |
| 256 | CTNM | Contineum Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.63 Bn | 0.00 Mn | — | 0.63 Bn |
| 257 | ARVN | Arvinas, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 0.00 Mn | 1.93 | 0.04 Bn |
| 258 | TECX | Tectonic Therapeutic, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | 0.00 Mn | — | 0.59 Bn |
| 259 | SGMT | Sagimet Biosciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 0.00 Mn | — | 0.58 Bn |
| 260 | VALN | Valneva SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | 551.06 Mn | 3.47 | 0.44 Bn |
| 261 | FLGT | Fulgent Genetics, Inc. | secondary | H-17 | Healthcare Providers | HG-04 | 0.56 Bn | 0.00 Mn | 2.30 | 0.30 Bn |
| 262 | OABI | OmniAb, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | 0.00 Mn | 14.37 | 0.50 Bn |
| 263 | OVID | Ovid Therapeutics Inc. | secondary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | 0.00 Mn | 348.63 | 0.43 Bn |
| 264 | IMUX | Immunic, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | 0.00 Mn | — | 0.55 Bn |
| 265 | PRLD | Prelude Therapeutics Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.54 Bn | 0.00 Mn | 24.04 | 0.26 Bn |
| 266 | PRTA | Prothena Corp Public Ltd Co | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | 0.00 Mn | 9.41 | 0.22 Bn |
| 267 | ANL | Adlai Nortye Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | 0.00 Mn | 78.36 | 0.27 Bn |
| 268 | RLMD | Relmada Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | 0.00 Mn | — | 0.50 Bn |
| 269 | CNTN | Canton Strategic Holdings, Inc. | secondary | T-58 | Fintech | TG-09 | 0.49 Bn | 0.00 Mn | 326.20 | 0.49 Bn |
| 270 | CCCC | C4 Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 14.06 | 0.24 Bn |
| 271 | KMDA | Kamada Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 2.56 | 0.42 Bn |
| 272 | PBYI | Puma Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.49 Bn | 0.00 Mn | 2.11 | 0.39 Bn |
| 273 | RZLT | Rezolute, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | 0.00 Mn | — | 0.48 Bn |
| 274 | NEUP | Neuphoria Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | — | 0.45 Bn |
| 275 | AVIR | Atea Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 0.00 Mn | — | 0.47 Bn |
| 276 | ARCT | Arcturus Therapeutics Holdings Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 15.31 | 0.26 Bn |
| 277 | DRUG | Bright Minds Biosciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | — | 0.23 Bn |
| 278 | CMPX | Compass Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | — | 0.45 Bn |
| 279 | EVMN | Evommune, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | 0.00 Mn | 44.52 | 0.24 Bn |
| 280 | CYPH | Cypherpunk Technologies Inc. | secondary | T-58 | Fintech | TG-09 | 0.44 Bn | 0.00 Mn | — | 0.44 Bn |
| 281 | BIOA | BioAge Labs, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.43 Bn | 0.00 Mn | 41.79 | 0.43 Bn |
| 282 | ENTA | Enanta Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | 0.00 Mn | 6.27 | 0.22 Bn |
| 283 | EYPT | EyePoint, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | 142.89 | 0.22 Bn |
| 284 | LRMR | Larimar Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | 0.00 Mn | — | 0.24 Bn |
| 285 | OFIX | Orthofix Medical Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 0.38 Bn | 0.00 Mn | 0.46 | 0.28 Bn |
| 286 | CATX | Perspective Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | — | 0.38 Bn |
| 287 | WHWK | Whitehawk Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | 0.00 Mn | — | 0.38 Bn |
| 288 | FHTX | Foghorn Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | 0.00 Mn | 9.47 | 0.28 Bn |
| 289 | ELDN | Eledon Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | — | 0.34 Bn |
| 290 | AGEN | Agenus Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | 0.00 Mn | 2.58 | 0.34 Bn |
| 291 | STRO | Sutro Biopharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | 3.72 | 0.17 Bn |
| 292 | EPRX | Eupraxia Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | — | 0.33 Bn |
| 293 | UPB | Upstream Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.33 Bn | 0.00 Mn | 103.85 | 0.33 Bn |
| 294 | GALT | Galectin Therapeutics Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 295 | BCYC | Bicycle Therapeutics Plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 4.90 | 0.30 Bn |
| 296 | TRDA | Entrada Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | 63.39 | 0.30 Bn |
| 297 | SABS | SAB Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | 0.00 Mn | — | 0.30 Bn |
| 298 | TLSI | TriSalus Life Sciences, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 0.29 Bn | 0.00 Mn | 6.48 | 0.25 Bn |
| 299 | ACIU | AC Immune SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 0.00 Mn | 12.87 | 0.29 Bn |
| 300 | MGNX | Macrogenics Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | 0.00 Mn | 1.70 | 0.17 Bn |